Innate Pharma to hold conference call August 14, 2026

Innate Pharma SA announced on August 14, 2026 that it would hold a conference call that day at 2:00 p.m. CEST, or 8:00 a.m. EDT.¹

Scheduled participants include Jonathan Dickinson, Chief Executive Officer, Yannis Morel, Executive Vice President and Chief Operating Officer, Frédéric Lombard, Senior Vice President and Chief Financial Officer, and Stéphanie Cornen, Vice President of Investor Relations and Communication.¹ The event will be accessible through a webcast link and a telephone registration link, both posted on the company's investor relations page. A replay of the webcast will be made available on the company's website afterward.¹

In its standard company description, Innate Pharma is described as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients.¹ Its proprietary pipeline centers on antibody-drug conjugates, led by IPH4502, a Nectin-4 ADC in clinical development for solid tumors, backed by a preclinical portfolio of additional ADC candidates.¹

The company also has two later-stage programs developed with partners: lacutamab, developed with Sobi for cutaneous T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer.¹ Innate Pharma has established collaborations with companies including Sobi, Sanofi, and AstraZeneca, along with academic and research institutions, in the immuno-oncology field.¹

Innate Pharma is headquartered in Marseille, France, and is listed on both Euronext Paris and Nasdaq in the United States.¹ The filing was submitted as a Form 6-K report for foreign private issuers under SEC rules, dated August 14, 2026, and signed by CEO Jonathan Dickinson.